Mizuho Maintains Outperform on Apogee Therapeutics, Raises Price Target to $110

Mizuho analyst Joseph Catanzaro has maintained an 'Outperform' rating on Apogee Therapeutics (NASDAQ: APGE) and raised the price target from $105 to $110. This adjustment reflects a positive outlook for the company's performance in the market.